ArticleDiscover oncology2025
Pharmacological inhibition of NMDA receptors reduces migration and viability in triple-negative inflammatory breast cancer cell lines.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.Molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeNMDA receptors (NMDARs), best known for their role in neuronal signaling, have been linked to breast cancer progression and metastasis, but their involvement in Inflammatory Breast Cancer (IBC) remains unexplored. IBC is a rare, invasive subtype with rapid progression, poor prognosis, and a high propensity for brain metastasis. Given the neuronal functions of NMDARs and IBC's high brain metastasis rates, we hypothesized that MNDARs may contribute to IBC's aggressive phenotype and represent a novel therapeutic target.
methodsIBC cell lines (SUM149PT and SUM190PT) and non-IBC controls (MBA-MB-231 and MCF7) were cultured in 2D and 3D systems to assess NMDAR mRNA and protein expression. Immunochemistry followed by confocal microscopy was performed to localize NMDARs within all cell lines. Functional studies tested the effects of NMDAR antagonist MK-801 (Dizocilpine) and Memantine on IBC's migration and 3D colony formation.
resultsNMDAR1 mRNA was significantly overexpressed in SUM149PT cells compared to MCF7, while NMDAR2B mRNA was significantly higher in both IBC lines. Protein analysis showed increased NMDAR1 in both IBC lines and NMDAR2B elevated only in SUM149PT. Immunochemistry and confocal microscopy confirmed both subunits in all lines, predominantly localized in cytoplasmic and perinuclear regions. Functionally, MK-801 reduced viability (IC
conclusionThis study provides the first evidence linking NMDARs to IBC progression. Elevated expression and inhibition-sensitive aggressive phenotypes suggest NMDARs as potential biomarkers and therapeutic targets in IBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.